To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

NCT00521378

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

COMPLETED

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

NCT02012166

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

NCT00111540

Diabetes Mellitus, Type 2

COMPLETED PHASE3

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

NCT03216226

Hypoglycemia Diabetes Mellitus, Type 1

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD1656

Group Type ACTIVE_COMPARATOR

AZD1656

Intervention Type DRUG

Single dose oral suspension given at one occasion.

2

Insulin

Group Type ACTIVE_COMPARATOR

Insulin

Intervention Type DRUG

Insulin infusion given during 3 hours at one occasion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin

Insulin infusion given during 3 hours at one occasion.

Intervention Type DRUG

AZD1656

Single dose oral suspension given at one occasion.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male volunteers.
* Clinically normal physical findings (incl. Electrocardiogram (ECG)) and laboratory values as judged by the investigator.
* Have a body mass index (BMI) ≥19 and ≤30

Exclusion Criteria

* Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
* Intake of any prescribed medicine and OTC drugs (including herbals, vitamins and minerals), except for occasional paracetamol or nasal spray for nasal congestion, within two weeks before the first administration of the investigational product.
* Daily use of nicotine containing substances.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes